| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
24,727 |
196,382 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,194,336 |
$28,520,846 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
20 |
73 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carr Patricia |
VP, Finance & PAO |
• – – |
2020-03-12 |
4 |
AS |
$102.17 |
$61,302 |
D/D |
(600) |
6,500 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2020-03-09 |
4 |
S |
$111.49 |
$68,566 |
D/D |
(615) |
13,883 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-03-09 |
4 |
S |
$111.45 |
$63,303 |
D/D |
(568) |
7,100 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2020-03-06 |
4 |
S |
$119.15 |
$34,793 |
D/D |
(292) |
14,498 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-03-06 |
4 |
S |
$119.17 |
$27,648 |
D/D |
(232) |
7,668 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-03-05 |
4 |
D |
$124.50 |
$1,876,340 |
D/D |
(15,071) |
340,033 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2020-03-05 |
4 |
D |
$124.50 |
$216,008 |
D/D |
(1,735) |
43,391 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2020-03-05 |
4 |
D |
$124.50 |
$301,664 |
D/D |
(2,423) |
23,618 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-03-04 |
4 |
AS |
$118.67 |
$30,024 |
D/D |
(253) |
7,900 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2020-03-03 |
4 |
S |
$119.75 |
$33,410 |
D/D |
(279) |
14,790 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-03-03 |
4 |
AS |
$119.75 |
$29,578 |
D/D |
(247) |
8,153 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
45,126 |
|
- |
|
| Iannone Robert |
EVP, Research & Development |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
10,800 |
23,000 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,600 |
8,400 |
|
- |
|
| Patil Neena M |
SVP, General Counsel |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
20,400 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
15,069 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
52,000 |
355,104 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2020-02-25 |
4 |
D |
$127.25 |
$67,443 |
D/D |
(530) |
26,041 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-02-25 |
4 |
D |
$127.25 |
$340,903 |
D/D |
(2,679) |
303,104 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-02-24 |
4 |
OE |
$11.48 |
$79,155 |
D/D |
6,895 |
305,783 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2020-02-13 |
4 |
AS |
$142.18 |
$213,270 |
D/D |
(1,500) |
26,571 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-02-03 |
4 |
AS |
$143.83 |
$143,830 |
D/D |
(1,000) |
298,888 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2020-01-03 |
4 |
D |
$146.09 |
$233,598 |
D/D |
(1,599) |
29,126 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2020-01-02 |
4 |
AS |
$149.51 |
$187,010 |
D/D |
(1,250) |
299,888 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2019-12-09 |
4 |
AS |
$149.12 |
$223,680 |
D/D |
(1,500) |
29,571 |
|
- |
|
881 Records found
|
|
Page 14 of 36 |
|
|
0.37 (0.34%) 
